Clinical Trial Results: What We Learned from Recent Phase 2 Trials in DLB

The Lewy Body Dementia Association (LBDA) is proud to present 'Clinical Trial Results: What We Learned from Recent Phase 2 Trials in DLB'.

In this session, Dr. James E. Galvin Professor of Neurology and Psychiatry & Behavioral Sciences at the University of Miami Miller School of Medicine and LBDA’s Director of Scientific Initiatives, Keith Fargo, Ph.D., shared recent findings, answered audience questions, and discussed upcoming LBD clinical trials, including how you can stay informed about them.

In the last 6 months, three Phase 2 clinical trials for investigational drugs in dementia with Lewy bodies (DLB) have reported results. This session broke down the findings, helped you understand new potential treatments and the need for Phase 3 trials, and highlighted how you can get involved in research.

Chapters:
00:00 - Introduction with Keith Fargo, PhD
06:25 - Introduction of James E. Galvin, MD, MPH
08:16 - Results of clinical trials
10:27 - Current approved treatments
17:40 - Enrollment table
32:14 - Biomarkers
44:41 - Summary
54:12 - Mechanisms of action

Ready to build on what you’ve learned? Join us Thursday, April 3 at 2pm ET, for our upcoming community webinar, ‘Navigating the Transition: Discussing PDD with Your Healthcare Team.’

Dr. Jennifer Goldman will share key insights on the cognitive challenges of Parkinson’s disease, including the differences between Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB). She will discuss early signs of cognitive decline, strategies for effective communication with healthcare providers, and resources to support individuals with PD and their care partners.

Don’t miss this opportunity to gain expert insights into the cognitive challenges of Parkinson’s disease and practical strategies for support.

Register Today: https://events.zoom.us/ev/AleKNl0fOgw...